Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EPS (Weighted Average and Diluted) (2016 - 2025)

Palisade Bio (PALI) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.38 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 83.62% to -$0.38 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.12, a 84.86% increase, with the full-year FY2024 number at -$10.19, up 62.27% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.38 for Q3 2025 at Palisade Bio, up from -$0.58 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.87 in Q4 2022 to a low of -$12.96 in Q1 2022.
  • A 5-year average of -$3.53 and a median of -$3.32 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 163.64% in 2021, then tumbled 8912.5% in 2023.
  • Palisade Bio's EPS (Weighted Average and Diluted) stood at $0.42 in 2021, then surged by 345.24% to $1.87 in 2022, then crashed by 301.6% to -$3.77 in 2023, then soared by 81.7% to -$0.69 in 2024, then skyrocketed by 44.93% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for PALI's EPS (Weighted Average and Diluted) are -$0.38 (Q3 2025), -$0.58 (Q2 2025), and -$0.47 (Q1 2025).